Results 101 to 110 of about 1,208 (169)

Efficacy of silymarinum at chronic diffuse liver diseases

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2011
The aim of review. To present modern data of foreign literature on efficacy of preparation of Silybum marianum – silymarinum at patients with alcoholinduced liver disease, non-alcoholic steatohepatosis and primary biliary cirrhosis.Original positions ...
A. V. Matvieiev, E. I. Konyaeva, N. V. Matvieieva   +2 more
doaj  

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes, Rishi S. Kotecha, Derek J. Roebuck   +2 more
wiley   +1 more source

Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
This study evaluated the performance of the PAGE‐B score in HCC risk among CHB patients with metabolic dysfunction or MASLD. The PAGE‐B score effectively stratified HCC risk in both MASLD and non‐MASLD patients, especially in those without cirrhosis, where low scores were linked to negligible 5‐year HCC risk. ABSTRACT Introduction Metabolic dysfunction
Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, Joep de Bruijne, Mark A. A. Claassen, Bettina E. Hansen, Robert A. de Man, Harry L. A. Janssen, R. Bart Takkenberg, Milan J. Sonneveld   +22 more
wiley   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi   +18 more
wiley   +1 more source

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death

Alimentary Pharmacology &Therapeutics, EarlyView.
Indocyanine green clearance by pulse dye densitometry correlates with portal hypertension, systemic inflammation and circulatory dysfunction in advanced chronic liver disease. While diagnostic accuracy for CSPH was limited, ICG‐R15 independently predicted decompensation and ACLF/liver‐related mortality, highlighting its prognostic value across disease ...
Mathias Jachs, Tânia Carvalho, Benedikt Simbrunner, Georg Semmler, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Paul Thöne, Nina Dominik, Georg Kramer, Christian Sebesta, Michael Schwarz, David Bauer, Albert F. Stättermayer, Matthias Pinter, Michael Trauner, Thomas Reiberger, Mattias Mandorfer   +17 more
wiley   +1 more source

Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt

Alimentary Pharmacology &Therapeutics, EarlyView.
Diabetes mellitus independently increases the risk of hepatic encephalopathy following TIPS placement in patients with cirrhosis. These findings emphasize the need for careful risk assessment in patients with cirrhosis and portal hypertension complications undergoing TIPS.
Michelle Spaan, Ellen Werner, Willemijn Dijkstra, Nicole E. Erler, Diederik Bijdevaate, Sarwa Darwish Murad, Milan J. Sonneveld, Caroline M. den Hoed, Anne van Eldere, Dave S. Sprengers, Willem‐Pieter Brouwer, Robert J. de Knegt, Harry L. A. Janssen, Kay Pieterman, Sandra Coenen, Raoel Maan, Adriaan J. van der Meer   +16 more
wiley   +1 more source

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation

Alimentary Pharmacology &Therapeutics, EarlyView.
Serum villin‐1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in acutely decompensated cirrhosis. Incorporating villin‐1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
David Tornai, Boglarka Balogh, Aniko Csillag, Andras Budai, Andras Kiss, Peter Antal‐Szalmas, Gabor Mehes, Lukacs Barath, Tamas Tornai, Istvan Tornai, Zsuzsanna Vitalis, Nora Sipeki, Tamas Dinya, Attila Enyedi, Florian A. Rosenberger, Wim Laleman, Minneke J. Coenraad, Ferran Aguilar, Joan Claria, Richard Moreau, Jonel Trebicka, Maria Papp, on behalf of MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium   +22 more
wiley   +1 more source

Development of NAFLD‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Cell Proliferation, EarlyView.
Microporous array organ chips were integrated with commercially available well plates to develop organoid chip platforms, which enable modelling of hepatic physiology and non‐alcoholic fatty liver disease (NAFLD) pathogenesis, as well as evaluation of semaglutide therapeutics. ABSTRACT Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate
Xiao‐yan You, Xiang‐yang Li, Hui Wang, Guo‐ping Zhao   +3 more
wiley   +1 more source

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

European Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Caterina Conte   +15 more
wiley   +1 more source